Is BCRX or BEAM more undervalued in 2026?

CirclFi compares BioCryst Pharmaceuticals, Inc. (BCRX) and Beam Therapeutics Inc. (BEAM) using 13 institutional-grade valuation models. BCRX has a Quality of Company score of 6.9/10 while BEAM scores 6.4/10.

Which is a better buy — BCRX or BEAM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BCRX and BEAM valuations compare?

BCRX at $8.91 and BEAM at $32.93 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BCRX vs BEAM Valuation Comparison 2026 — Intrinsic Value Analysis

BCRX

Biological Products, (No Diagnostic Substances)

BioCryst Pharmaceuticals, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$8.91

Last close

Models

12/13

Active

BEAM

Biological Products, (No Diagnostic Substances)

Beam Therapeutics Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$32.93

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	BCRX Fair Value	BCRX Upside	BEAM Fair Value	BEAM Upside
Bayesian DCF	Intrinsic	$14.22	+66.7%	$8.58	-74.0%
Earnings Power Value	Intrinsic	$2.33	-74.2%	$15.21	-43.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCRX vs BEAM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCRX vs BEAM — Which Stock Is More Undervalued?

BCRX scores higher with a 6.9/10 quality rating vs BEAM's 6.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BioCryst Pharmaceuticals, Inc. (BCRX) and Beam Therapeutics Inc. (BEAM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCRX currently trades at $8.91 with a QOC of 6.9/10, while BEAM trades at $32.93 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).